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Abstract
Background
Allergen-specific immunotherapy (AIT) is the only curative treatment for type-1 allergies, but
sometimes shows limited therapeutic response as well as local and systemic side effects.
Limited control of local inflammation and patient symptoms hampers its widespread use in
severe allergic asthma.
Objective
Our aim was to evaluate whether AIT is more effective in suppression of local inflammation
if performed under the umbrella of short-term non-specific immunomodulation using a small
molecule inhibitor of JAK pathways.
Methods
In C57BL/6J mice, a model of ovalbumin (OVA)-induced allergic airway inflammation and
allergen-specific immunotherapy was combined with the administration of Tofacitinib
(TOFA, a FDA-approved JAK inhibitor) from 48 hours prior to 48 hours after therapeutic
OVA-injection. The effect of TOFA on human FOXP3+CD4+ T cells was studied in vitro.
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Results
AIT combined with short-term TOFA administration was significantly more effective in sup-
pressing total cell and eosinophil infiltration into the lung, local cytokine production including
IL-1β and CXCL1 and showed a trend for the reduction of IL-4, IL-13, TNF-α and IL-6 com-
pared to AIT alone. Furthermore, TOFA co-administration significantly reduced systemic IL-
6, IL-1β and OVA-specific IgE levels and induced IgG1 to the same extent as AIT alone.
Additionally, TOFA enhanced the induction of human FOXP3+CD4+ T cells.
Conclusions
This proof of concept study shows that JAK inhibition did not inhibit tolerance induction, but
improved experimental AIT at the level of local inflammation. The improved control of local
inflammation might extend the use of AIT in more severe conditions such as polyallergy,
asthma and high-risk patients suffering from mastocytosis or anaphylaxis.
Introduction
Allergen-specific immunotherapy (AIT) is the only curative therapy for allergic diseases,
which is able to maintain its efficacy after discontinuation of treatment and which may signifi-
cantly reduce allergic symptoms [1–3]. However, the therapeutic allergen exposure initially
boosts allergic pathways, e.g. by increasing IgE secretion by B cells, success rates vary and
patient compliance is low due to long treatment regimens. Moreover, the indication of AIT is
mainly limited to allergic rhinitis and mild asthma, while this treatment is contra-indicated in
severe allergic asthma [4] and of limited help in polyallergic rhinitis patients and atopic eczema
[5]. Additionally, combining AIT with an anti-inflammatory therapy might facilitate the
reduction of side effects and the acceleration of the titration phase.
Therefore, it is highly desirable that curative success of up to 95% in selected indications
such as hymenoptera venom allergy [6] can also be translated into the tolerogenic vaccination
of difficult-to-treat allergies affecting the respiratory tract, eyes or gut. Furthermore, it is of
considerable interest to extend the application of AIT to atopic eczema and polyallergic
patients, where this treatment is less efficient, because the local inflammatory process is not
only causing side effects, but also impairs the induction of immune tolerance [7]. Hence, a vac-
cination-induced antigen presentation in the absence of inflammatory signals, induced by
short-term JAK-pathway inhibition of inflammation, might facilitate the induction of immu-
nological tolerance.
The mechanisms underlying the induction of allergen-specific immune tolerance are
incompletely understood. To date, the induction of allergen-specific IgG4 and a change of the
pro-allergic T cell phenotype are assumed to underlie long-lasting treatment benefits [8, 9].
Regulatory T cells (Tregs) were reported to be induced by AIT [10, 11] and may play a role in
suppressing pro-allergic Th2 cells [12]. It is currently unclear how the induction of regulatory
T cells can be facilitated in the context of antigen-specific vaccination. However, it appears
that allergic inflammation, specifically IL-4-mediated inhibition of the FOXP3 promoter [13],
can directly inhibit the induction of regulatory T cells. Similarly, other pro-inflammatory
mediators are counteracting Treg induction [14].
Consequently, the use of immunomodulating drugs may promote the induction of Tregs as
long as they do not block signals that are necessary for the differentiation of Tregs. While
JAK inhibition during specific immunotherapy
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Cyclosporine A inhibits the induction of Tregs [15] and Corticosteroids are only minimally
promoting Tregs [16, 17], it was shown that Janus kinase (JAK) inhibitors preserve the Treg
function [18]. JAKs are key players in cytokine-mediated activation of STATs (signal transduc-
ers and activators of transcription) and, therefore, of inflammatory processes [19]. The current
study assessed the impact of short-term application of the FDA-approved JAK inhibitor Tofa-
citinib (TOFA) [20] on therapy outcome in a murine model of OVA (chicken ovalbumin)-spe-
cific immunotherapy. Moreover, the effect of TOFA on FOXP3 expression in human T cells
was addressed. We hypothesized that the efficacy of AIT might be facilitated by the anti-
inflammatory effects of TOFA administration for short periods of 5 days during the up-dosing
phase, which are uncritical with respect to TOFA-mediated side effects [21].
Methods
Animals
Female C57BL/6J mice (Charles River, Sulzfeld, Germany) were housed under specific patho-
gen free conditions in GM500 cages, including individually ventilated caging systems (IVC
System Green Line, Tecniplast, Buguggiate, Italy), which are operated with positive pressure.
The mice are transferred to new cages with forceps in Laminar Flow Class II changing stations
weekly; they are fed with an irradiated standard rodent high energy breeding diet (Altromin
1314, Altromin Spezialfutter GmbH & Co. KG, Lippe, Germany) and have access ad libitum to
semi-demineralized filtered (0.2 mm) water. The light cycle is adjusted to a 12h/12h light/dark
cycle; room temperature is regulated to 22 +/- 1˚C and relative humidity to 55 +/- 5%. Hus-
bandry conditions are adjusted to the experimental requirements in specified modules. Senti-
nels (outbred 8-week-old male SPF Swiss mice) are housed on a mixture (50:50) of new
bedding material and a mixture of soiled bedding from all cages of this IVC rack and their
health is monitored by on-site examination of certified laboratories according to the FELASA
recommendations (http://www.felasa.org). All animal experiments were carried out in accor-
dance with German legal guidelines and following the approval (approval number 55.2-1-54-
2532-30-14) of the responsible animal welfare authorities and the ethics board of the district
government of Upper Bavaria, Germany. Animals were monitored every day after in vivo
intervention, otherwise weekly. The facility follows a surveillance protocol, which indicates
early endpoints such as strong bodyweight loss, abnormal coat/behavior or issues related to
infections. If any of these clinical signs were reached prior to the experimental endpoint, the
animals were euthanized. Euthanasia was carried out by an overdose of Ketamin/Xylazine.
Within the presented experiments, none of the animals died prior to the experimental
endpoint.
Allergen sensitization and AIT model
For allergic sensitization, mice were treated twice by intraperitoneal injection of 10 μg OVA
(chicken ovalbumin; Sigma-Aldrich, Taufkirchen, Germany) and 0.5 mg aluminum hydroxide
(imject1 Alum; 40 mg magnesium/40 mg alum per mL; Thermo Fischer Scientific, Waltham,
MA USA) in 200 μl phosphate buffered saline (PBS) at day (D)-1 and D-7 as previously
described [22, 23]. Subsequently, mice were challenged by inhalative exposure to OVA aerosol
(1% in PBS) for 10 min once a day at D-49, 52 and 55. 24 h after the last challenge, blood sam-
ples were collected by puncturing the retro-orbital plexus (Li-heparin-coated tubes, KADE,
Nu¨mbrecht, Germany) under isoflurane anesthesia [22–24]. Blood samples were centrifuged
(10 min, 5000 x g, 4˚C) to separate cells and plasma. Animals were sacrificed to obtain bronch-
oalveolar lavage (BAL) samples as previously described [25].
JAK inhibition during specific immunotherapy
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For allergen-specific-immunotherapy (AIT), animals were treated by subcutaneous injec-
tion of 1 mg OVA at D-22, and 0.5 mg OVA at D-29. For treatment with Tofacitinib (TOFA),
(Tofacitinib citrate; CP-690550; Selleckchem-Biozol Diagnostica Vertrieb GmbH, Eching,
Germany, dissolved to 50 mg/ml in sterile DMSO) two doses per day were administered on D-
20 to D-24, and D-27 to D-31 by oral gavage feeding (10.8 mg/kg in 200 μl water).
Controls and treatment protocol
Within one experimental setup, statistically calculated to reach highly significant results, we
treated and analyzed the following groups (n = 9–14) of mice:
Non-allergic: non-sensitized mice, exposed to OVA-aerosol only.
Allergic: mice sensitized with OVA and exposed to OVA-aerosol (challenge).
Allergic-AIT: mice sensitized with OVA, treated with OVA-AIT and challenged with OVA
aerosol.
Allergic-AIT + TOFA: mice sensitized with OVA, treated with OVA-AIT with concomitant
gastric TOFA feeding and subsequent exposure to OVA-aerosol (Fig 1).
Allergic + TOFA: mice sensitized with OVA, treated with gastric TOFA feeding and subse-
quent exposure to OVA-aerosol.
Fig 1. Schematic overview about the different in vivo treatment schemes (sensitization, AIT, TOFA
administration, challenge). The treatment of four experimental groups of mice (n = 9–14) is shown. AIT,
allergen-specific immunotherapy; i.p, intraperitoneal; s.c., subcutaneous.
https://doi.org/10.1371/journal.pone.0178563.g001
JAK inhibition during specific immunotherapy
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Measurement of antibodies in plasma
For the determination of total IgE levels, plasma samples and standards (mouse IgE clone
C38-2; BD Pharmingen, Heidelberg, Germany) were transferred to microtiter plates, coated
with 10 μg/mL monoclonal rat anti-mouse-IgE (IgG, clone-PC 284; The Binding Site, Schwet-
zingen, Germany). For OVA-specific IgE measurement, plasma samples and standards
(mouse IgE anti-Ovalbumin clone: 2C6; Biozol, Eching, Germany) were transferred to micro-
titer plates coated with 2 μg/mL of OVA (chicken ovalbumin, Sigma, Germany). As secondary
antibody, 2.5 μg/mL of biotinylated monoclonal rat anti-mouse IgE (clone R35-118; BD Phar-
mingen) were used, followed by incubation with BD OptEIA Reagent Set B (BD Pharmingen).
Signal intensities were measured at 450 nm. The determination of further immunoglobulin
isotype levels was performed with a combined electrochemiluminescence multiplexed assay
system (Meso Scale Discovery, MSD, Rockville, MD USA).
Measurement of cells in BAL fluid
Flow cytometry of BAL cells was performed by using the following monoclonal antibodies:
anti-CD8a-AlexaFlour750 (clone 5H10, Thermo Fisher Scientific; AB_10374588), anti-Ly6c-
FITC (clone AL-21, BD Biosciences, San Jose, CA USA; AB_394628), anti-CD4-PerCP-Cy5.5
(clone RM 4–5, BD Biosciences; AB_393977), anti-CD62L-PE-Cy7 (clone MEL-14,
eBioscience, affymetrix, Frankfurt am Main, Germany; AB_469632), anti-CD3-eFlour450
(clone 17A2, eBiosciene; AB_1272229), anti-CD25-APC (clone PC61, BD Biosciences;
AB_398623), anti-Gr1-PacificOrange (clone Rb6-8C5, Thermo Fisher Scientific;
AB_2556571), anti-CD19-PE-Cy7 (clone 1D3, BD Biosciences; AB_10894021), anti-CD11b-
APC-Cy7 (clone M1/70; BD Biosciences; AB_396772), anti-CD11c-FITC (clone HL 3, BD Bio-
sciences; AB_395060), anti-CD45-AlexaFlour700 (clone 30-F11, BioLegend, San Diego, CA
USA; AB_493714), anti-F4/80-APC (clone BM8, eBioscience; AB_469451) and anti-MHC-II
(I-A/I-E)-PerCP-Cy5.5 (clone M5/114.15.2, BioLegend; AB_2191072) [23]. Data were
acquired using a LSRII flow cytometer (BD Bioscience) and further analyzed with FACSDiva
software (BD Biosciences) and FlowJo V.7.2.2 (Tree star, Ashland, USA). The gating strategy is
displayed in S1 Fig.
Histological analysis of the lung
After BAL, the lungs were removed and snap frozen in liquid nitrogen. For histological analy-
sis, lungs were post-fixed in 4% buffered formaldehyde solution, dehydrated and embedded in
paraffin. Four μm sections were stained with hematoxylin-eosin and periodic acid-Schiff
(PAS).
Cytokine measurements
Pro-inflammatory cytokines from BAL and plasma were analyzed by an electrochemilumines-
cence multiplex assay (Meso Scale Discovery, MSD). IL-13 and IL-17 were measured using the
kits Mouse IL-13 CytoSet (Thermo Fisher Scientific) and Mouse IL-17A ELISA Max (BioLe-
gend) according to manufacturer’s recommendations.
Statistical analyses
Gaussian distribution was tested by D’Agostino & Pearson omnibus normality test. Gaussian
and non-Gaussian distributed results were further analyzed by unpaired t test or Mann Whit-
ney test, respectively (GraphPad Prism, San Diego, CA, USA). P-values of>0.05,0.05,
0.01,0.001 and0.0001 are shown as ns, , , , and, , respectively.
JAK inhibition during specific immunotherapy
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Human blood donors
For the T cell differentiation assay, naive T cells were isolated from the blood of 3 healthy
donors (2 female, 1 male). The study was approved by the local ethics committee of the Tech-
nical University Munich, ethics board no 2877/10, and all individuals gave informed written
consent.
Differentiation of human naive CD4+ T cells into FOXP3+CD4+ T cells
Human peripheral blood mononuclear cells were isolated from heparinized whole blood by
standard density gradient centrifugation (Lymphoprep, Axis Shield, Oslo, Norway). Naive
CD4+ T cells were isolated using the Naive CD4+ T cell Kit II (Miltenyi Biotec, Bergisch Glad-
bach, Germany) and by additional depletion of CD45RO+ cells (CD45RO microbeads, Milte-
nyi Biotec). Cells were cultured in RPMI 1640 (Thermo Fisher Scientific) complete (10% FCS,
Biochrom, Merck, Berlin, Germany; 2mM L-glutamine, 100 U/mL Penicillin/Streptomycin,
Thermo Fisher Scientific) in 24-well plates at a concentration of 1x106 cells/mL at 37˚C. After
isolation, cells were stimulated with plate-bound anti-CD3 (10 μg/mL; clone UCHT1, mono-
clonal, BD Biosciences; AB_395736) and 2 μg/mL anti-CD28 (clone CD28.2, monoclonal, BD
Biosciences, 2 μg/mL; AB_396068) in solution and cultured for five days. To induce FOXP3
expression, the culture medium was supplemented with 50 U/mL rIL-2 (Novartis, Nu¨rnberg,
Germany) and 5 ng/mL TGF-β1 (Promokine). Beneath this control, cells were cultured in the
presence of different concentrations of TOFA, Rapamycin (Sigma-Aldrich) and Cyclosporine
A (Sigma-Aldrich). After three days of culture, half of the medium was removed and replaced
by fresh RPMI 1640 complete, supplemented with the same doses of cytokines and agents as at
day 0.
After five days of culture, the cells were washed with ice-cold PBS and stained with LIVE/
DEAD Fixable Aqua Dead Cell Stain Kit (Thermo Fisher Scientific) according to the manufac-
turer’s protocol. Moreover the cells were stained 1:300 with anti-CD4-Alexa Flour700 (clone
RPA-T4, monoclonal, BioLegend; AB_493743) and 1:100 with anti-FOXP3-eFlour450 (clone
PCH101, monoclonal, eBioscience; AB_1834365) by using the FOXP3/Transcription Factor
Staining Buffer Set (eBioscience, affymetrix) according to manufacturer’s protocol. The acqui-
sition of cells was performed with BD FACSDIVA 7.0 on a BD LSR Fortessa (BD Biosciences).
Data were analyzed with the software FlowJo (Tree Star, Ashland, OR), the lymphocyte popu-
lation was gated on CD4+ cells and dead cells were excluded from the analysis.
Results
Effect of AIT and JAK inhibition on lung cell infiltration
Sensitization and challenge with OVA (Fig 1) resulted in a massive cell infiltrate (median
31-fold compared to the non-allergic/OVA-challenged mice) in the BAL fluid, which was
dominated by eosinophils (1279-fold) (Fig 2). AIT ameliorated OVA-induced total BAL cell
infiltration in allergic-AIT mice by 87% compared to allergic mice. The combination treat-
ment with AIT and TOFA led to further significant suppression of the BAL infiltrate to 93%
(Fig 2A).
Moreover, AIT improved OVA-induced eosinophil BAL cell infiltration to 63% (median)
compared to 81% in allergic mice. An additional significant reduction of eosinophil infiltration
to approximately 48% was achieved by co-administration of TOFA (Fig 2B). This reduction
was accompanied by a significant relative increase of macrophages, neutrophils and
lymphocytes.
JAK inhibition during specific immunotherapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0178563 June 1, 2017 6 / 18
Fig 2. Analysis of the cellular BAL fluid compartment and lung histology of mice (Non-allergic,
Allergic, Allergic-AIT, Allergic-AIT+TOFA) after OVA-aerosol challenge. (A) Counts of total BAL cells and
total cell count of eosinophils, macrophages, neutrophils and lymphocytes. (B) Relative percentages of
eosinophils, macrophages, neutrophils and lymphocytes within the total BAL cells. Shown is the median with
range. Gaussian and non-Gaussian distributed results were analyzed by unpaired t test or Mann Whitney test,
JAK inhibition during specific immunotherapy
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In contrast to non-allergic mice (Fig 2C) strong perivascular, peribronchiolar and alveolar
inflammatory cell infiltration characterized by a strong eosinophilia was observed in the lungs
of allergic mice (Fig 2D) and this effect was substantially reduced by AIT (Fig 2E) and even
further by the combination of AIT and TOFA (Fig 2F). However, no reduction in PAS positive
material was seen following AIT and AIT in combination with TOFA (data not shown).
Of note, TOFA treatment without AIT was not able to induce any of these effects, verifying
that no transient immunosuppression was responsible for the obtained results (Fig 3). Here,
analyses were performed in week 6 to assess the time of complete wash-out of TOFA and to
avoid transient TOFA mediated effects on experimental AIT (Fig 3A). In detail, TOFA treat-
ment alone had no effect on immunoglobulin levels in plasma (Fig 3B), only slightly reduced
the total cell number in the BAL fluid (Fig 3C), but had no effect on eosinophilic infiltration
into the BAL fluid (Fig 3D) or on inflammatory cell infiltration in lung tissue (Fig 3E–3F).
Moreover, no effects of TOFA-treatment without AIT on cytokine levels in the BAL fluid were
observed (Fig 3G).
Effect of AIT and JAK inhibition on cytokine secretion in BAL fluid
After OVA challenge the amount of several cytokines in the BAL fluid was assessed. Intrigu-
ingly, AIT induced a dramatic reduction of monokine secretion (IL-1β, IL-6 and TNF-α) into
the BAL fluid (reduction to 20% of Il-1β, 18% of IL-6 and 16% of TNF-α compared to allergic
mice) (Fig 4). The combination of AIT plus TOFA was even more potent (reduction of both
Il-1β and IL-6 levels to 11%, and TNF-α levels to 10% compared to allergic mice). The addition
of TOFA to AIT led to significantly reduced IL-1β secretion compared to AIT alone, while a
tendency was observed for further reduction of IL-6 and TNF-α secretion.
A similar enhancement of inhibition by AIT and the combination of AIT and TOFA
(median 78% and 56% compared to allergic mice) was observed for the chemokine CXCL1,
the murine homologue of human IL-8, whereby only the addition of TOFA led to a significant
reduction (Fig 4). In contrast, T cell cytokines IL-2 and IFN-γ were barely detectable and mar-
ginally reduced by AIT without further effect by concomitant TOFA treatment. While OVA
challenge resulted in measurable amounts of IL-17A in non-allergic and allergic mice, this
cytokine was not detectable in most mice after treatment with AIT or the combination of AIT
and TOFA.
AIT significantly reduced the secretion of the Th2-cytokines IL-4 and IL-13 into BAL fluid
and a tendency towards further decrease by the combination of AIT and TOFA was observed.
In addition, the level of IL-10 in the BAL fluid was significantly decreased by AIT ant the com-
bination of AIT and TOFA. However, both treatment regimens slightly increased IL-5 secre-
tion (Fig 4).
Effect of AIT and JAK inhibition on antibody levels
Sensitization of mice with OVA resulted in the induction of OVA-specific IgE (Fig 5A, left
panel). While only a tendency towards reduced sIgE was achieved by AIT alone, the combina-
tion treatment of AIT and TOFA resulted in a highly significant decrease of the amount of
sIgE, which was comparable to that of non-allergic mice. Moreover, treatment of mice with
AIT and the combination of AIT and TOFA led to an increasing tendency of reduced total IgE
respectively. (C-F): Lung histology (H&E staining). (C) Non-allergic. (D) Allergic. (E) Allergic-AIT. (F) Allergic-
AIT + TOFA. Arrows indicate inflammatory infiltrates; scale bar: 50 μm.
https://doi.org/10.1371/journal.pone.0178563.g002
JAK inhibition during specific immunotherapy
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Fig 3. Effect of TOFA on allergic sensitization. (A) Schematic overview about the different in vivo treatment schemes
(sensitization, TOFA administration, challenge) for two experimental groups of mice (n = 10). i.p, intraperitoneal. (B)
Immunoglobulin measurements in plasma samples. (C) Counts of total BAL cells. (D) Relative percentages of eosinophils,
macrophages, neutrophils and lymphocytes within the total BAL cells. Shown is the median with range. (E-F) Lung
histology (H&E staining). (E) Allergic. (F) Allergic + TOFA. Arrows indicate inflammatory infiltrates; scale bar: 50 μm. (G)
JAK inhibition during specific immunotherapy
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levels (median 56.5% and 42.2% compared to allergic mice (Fig 5A, middle panel). Addition-
ally, AIT as well as the combination of AIT and TOFA resulted in a highly significant increase
of total IgG1 levels compared to the allergic mice (Fig 5A, right panel). The levels of IgM, IgA,
IgG2b and IgG3 were not affected by AIT or the combination of AIT and TOFA (data not
shown).
Effect of AIT and JAK inhibition on systemic cytokine levels
Non-allergic and allergic mice showed comparable levels of IL-6 in plasma after OVA-aerosol
challenge. Interestingly, a reduction of the IL-6 plasma level was detected in mice after AIT
(median 56% compared to allergic mice) with further significant reduction in mice treated
with AIT and TOFA (median 38% compared to allergic mice) (Fig 5B). A similar enhancement
of inhibition (41% and 75%) was observed for IL-1β. While AIT was able to reduce the IL-1β
level to 60% compared to allergic mice, the combination of AIT and TOFA further decreased
the level to 25%. Additionally, the co-administration of AIT and TOFA, in contrast to AIT
alone, was able to reduce the level of IL-2 to the level of non-allergic mice. Interestingly, the
level of IL-17A was only increased in allergic mice while it was comparable in non-allergic
mice and mice treated with AIT or the combination of AIT and TOFA. IL-4, IL-13, IL-5, TNF-
α, INF-γ, CXCL1 and IL-10 were barely detectable in plasma or showed only non-significant
differences between different groups (S2 Fig).
Tofacitinib facilitates the differentiation of human FOXP3+CD4+ T cells
Since the suppressive effect of TOFA on human and murine Th1/Th2/Th17 effector cells and
immunoglobulin secretion has been shown previously [18], we analyzed the Treg-induction as
important immune tolerance mechanism. In order to obtain insights into the effect of TOFA
and other immune-modulating agents such as Rapamycin and Cyclosporine A on FOXP3
expression in human CD4+ T cells, naive CD4+ T cells (purity 95–98%, data not shown) were
isolated from healthy human blood donors (n = 3) and cultured in the presence of TGF-β1, IL-
2 and different concentrations of the immune modulators. For the control cells, cultured
under iTreg (induced regulatory T cell)-polarizing conditions without immune modulators,
17.7–43.6% FOXP3+ cells within the living CD4+ T cell population were detected (Fig 6). The
two lower doses of TOFA were able to enhance the induction of FOXP3 expression within this
T cell compartment (Fig 6). For a concentration of 0.1 μM and 1 μM TOFA in the culture
medium 57.2–77.1% and 51.1–70.6% FOXP3 producing cells were detected, respectively. On
average 0.1 μM and 1 μM TOFA were able to increase the percentage of FOXP3 expressing
cells about 2.4 (+/- 0.7) − 2.5 (+/-1.3)-fold. The concentration of 10 μM of TOFA induced cyto-
toxicity (data not shown) and diminished the FOXP3-enhancing effect. Rapamycin treatment
did not inhibit FOXP3 expression and resulted in 1.3-fold higher expression. The lowest con-
centration of Cyclosporine A (0.003 μM) showed no effect on FOXP3 induction, whereas the
two higher concentrations (0.033 μM, 0.333 μM) reduced the percentage of FOXP3+ cells
within the CD4+ T cell compartment. The obtained results were consistent for all individual
donors (Fig 6B).
Results of cytokine measurements in the BAL fluid. Bars indicate the median. Gaussian and non-Gaussian distributed
results were analyzed by unpaired t test or Mann Whitney test, respectively.
https://doi.org/10.1371/journal.pone.0178563.g003
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Fig 4. Analysis of the soluble BAL fluid compartment (Non-allergic, Allergic, Allergic-AIT, Allergic-AIT
+TOFA) after OVA-aerosol challenge. Results of the cytokine measurement for IL-4, IL-13, IL-5, IL-17A, IL-6,
TNF-α, IL-2, IL-1β, IL-10, IL-12p70, IFN-γ and CXCL1. Bars indicate the median. Gaussian and non-Gaussian
distributed results were analyzed by unpaired t test or Mann Whitney test, respectively.
https://doi.org/10.1371/journal.pone.0178563.g004
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Discussion
In order to identify immune modulators which have the potential to improve the efficacy of
allergen-specific immunotherapy we addressed the beneficial effect of Tofacitinib during AIT.
The rationale behind this combinatorial approach is that vaccination-induced antigen presen-
tation in the absence of inflammatory signals might facilitate the induction of immunological
tolerance [26]. So far, the effects of the application of JAK inhibitors during AIT have not been
reported.
In this study we used a murine model of OVA-induced allergy and subsequent experimen-
tal AIT, similar to the model previously described by Vissers et al. [27]. In our model the appli-
cation of TOFA in combination with AIT was able to improve several key parameters of
Fig 5. Analysis of murine plasma samples (Non-allergic, Allergic, Allergic-AIT, Allergic-AIT+TOFA) after OVA-
aerosol challenge. (A) Results of the immunoglobulin measurement for OVA-specific IgE, total IgE and total IgG1, and (B)
results of the cytokine measurement for IL-6, IL-1β, IL-2 and IL-17A. Bars indicate the median. Gaussian and non-Gaussian
distributed results were analyzed by unpaired t test or Mann Whitney test, respectively.
https://doi.org/10.1371/journal.pone.0178563.g005
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Fig 6. Effect of TOFA on the differentiation of human FOXP3+CD4+ T cells. Naive CD4+ T cells of human
blood donors (n = 3) were stimulated with anti-CD3/anti-CD28, IL-2 and TGF-β1 to induce FOXP3 expression.
In addition to this polarization control, TOFA, Rapamycin or Cycloysporine A were added to the medium in
different concentrations. (A) Flow cytometry plots of anti-CD4 and anti-FOXP3 staining are shown for one
representative donor. (B) The percentages of FOXP3+ cells within the living CD4+ T cell population under
control, TOFA, Rapamycin and Cyclosporine A condition is given for the three donors. Bars indicate the
median.
https://doi.org/10.1371/journal.pone.0178563.g006
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allergic airway inflammation, such as total cell and particularly eosinophilic infiltration into
the BAL fluid, levels of the Th2 cytokines IL-4 and IL-13, the monokines IL-1β, IL-6 and TNF-
α as well as IL-17A and CXCL1. Moreover, OVA-specific as well as total IgE levels were clearly
reduced. Particularly sIgE levels could only be reduced with high significance by the co-admin-
istration of AIT and TOFA. Moreover, a systemic inhibition of pro-inflammatory cytokines
was observed. Hence, the inhibition of the JAK 1 and 3 pathways demonstrates clear potential
for further improvement of specific immunotherapy. Although TOFA shows the highest selec-
tivity for JAK1 and 3, effects by the weaker inhibition of JAK 2 and TYK2 are known [28].
However, we could show that the improved efficacy of AIT mediated by TOFA is not primarily
due to an inhibition of cellular immunologic effector functions, but also by the functional and
robust induction of potentially protective IgG1 antibodies. Furthermore, comparable effects
on airway eosinophilia and Th2 cytokine production were previously described for the admin-
istration of the highly selective JAK1/3 inhibitor R256 during the sensitization and allergen
challenge phase [29].
Key problems of human AIT are the side effects, such as local swelling, granuloma forma-
tion, anaphylaxis, as well as often insufficient clinical responses, which are related to local
inflammatory conditions [4]. Therefore, the aim of short-term administration of TOFA during
AIT is not a long-lasting modification of the JAK/STAT pathway but rather a short-term
blockade of this signaling cascade to restrict local inflammation and to support the tolerogenic
memory effect induced by AIT. This study demonstrates that TOFA-mediated JAK inhibition
can significantly support AIT-mediated control of local inflammation, in particular the Th2
dependent influx of eosinophils.
Although the analysis of clinical trials is too multifactorial and requires large sample sizes, it
can be anticipated that eosinophil reduction positively relates to clinical efficacy [12]. The
TOFA-mediated downregulation of eosinophil infiltration is not related to Th2 cytokines, in
particular IL-5, which was not decreased by AIT or AIT in combination with TOFA. Interest-
ingly, IL-4 and IL-13 were downregulated by AIT and the combination of AIT and TOFA.
Since the genes of IL-4 and IL-5 are situated on the same genomic locus [30], it is unlikely that
the differential secretion levels originate from the same cells, but rather are a result of different
cell origin such as Th2 cells and innate lymphoid type 2 cells [31]. In addition the level of IL-10
in the BAL fluid, which is also produced by Th2 cells [32], was downregulated by AIT and the
combination of AIT and TOFA. Unfortunately, our study lacks lung function measurements,
which would enhance its clinical relevance.
The induction of IgG1 by AIT is in line with previous studies, which have shown that AIT
with OVA in murine allergic airway disease induces OVA-specific IgG1 [33]. It is of major
importance that this induction of potentially protective antibodies is not affected by TOFA
administration. Recently, a study focusing on the effects of TOFA treatment on human B cells
showed results broadening our findings for the human situation. Rizzi et al demonstrated that
in vitro TOFA treatment does not inhibit class switching during B cell maturation and only
diminishes plasmablast formation and immunoglobulin secretion in naive B cells for a short
period. B cells isolated from TOFA-treated patients could be again activated to differentiate
into plasmablasts and these plasmablasts secreted immunoglobulin levels comparable or
slightly increased to normal levels [34]. We might speculate that during the short-term TOFA
treatment combined to AIT, we inhibit the prompt formation of IgE producing plasmablasts
and create a window of opportunity for the class switching to IgG. Allergen-IgG complexes
can then further induce IgG1 and the secretion of macrophage-derived IL-10, which is an
important mediator of immune tolerance in experimental murine AIT [35, 36]. These IgG1
antibodies are believed to compete with IgE in a similar way as IgG4 in the human system,
what in turn prevents mediator release from sensitized mast cells [9, 10]. However, the
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reduction of the Th2-late phase response with eosinophil infiltration in the BAL-fluid is inde-
pendent of B cell function and IgG-production [33].
The effect of TOFA-enhanced AIT was most pronounced among monokines IL-1β, TNF-α
and IL-6. The mean terminal plasma half-life of TOFA is 3.2 hours [37] and it has been previ-
ously shown that discontinuation of TOFA after short-term treatment in vitro allows normal
reactivation of lymphocytes within four days [38]. Therefore, the effect at the time point of
aerosol allergen challenge cannot be attributed to the transient action of TOFA, since the last
application of TOFA was given 18 days before. The reduction of IL-6 has also been observed in
a four weeks clinical trial assessing TOFA for rheumatoid arthritis [39]. Taken together, it is
likely that resident epithelial cells (e.g. bronchial/ alveolar or liver epithelial cells) mediate the
reduction of pro-inflammatory mediators, as it was shown in a recent model of graft-versus
host disease for keratinocyte-derived CXCL9 and CXCL10 [40]. It is currently unknown,
whether the TOFA-mediated reduction of IL-1β responses are caused by a long-lasting effect
on airway- or liver epithelial cells or by AIT-modulated T cell responses affecting epithelium-
regulating cytokines.
Interestingly, we were able to demonstrate that TOFA administration in vitro favored the
induction of human FOXP3+CD4+ T cells, a hallmark of T cell tolerance [12]. This extends the
findings of an earlier study, which demonstrated that TOFA preserves the function of regula-
tory T cells and inhibits effector T cells [18]. In contrast, other immunosuppressive drugs such
as Cyclosporine A inhibit FOXP3-mediated Treg induction [15]. We previously demonstrated
that this effect depends on direct inhibition of NFAT (nuclear factor of activated T cells) bind-
ing to the proximal FOXP3 promoter [41].
Our data demonstrate that JAK-inhibitors are able to shift the balance of newly induced T
cell reactivity. This potentially favors the induction of functional regulatory T cells, which
build the basis for a long-lasting modulation of the immunological memory and which are
beneficial for the treatment of a variety of immune diseases. Additionally, this hypothesis is
supported by a recent study of a murine autoimmune disease model, showing the antigen-spe-
cific induction of Tregs and a decrease of Th1 and Th17 by dendritic cells treated with TOFA
in vitro [42].
Conclusion
Taken together the current study shows that the combination treatment of AIT with a JAK
inhibitor amplifies the clinical efficacy of AIT, as it not only influences adaptive, but also the
innate arm of immune responses. The promising preclinical data on the long-lasting effects on
local and systemic inflammation pave the way towards the set-up of human clinical trials.
These trials could open up the chance to further minimize local and systemic side effects, even
during seasonal treatment or in polysensitized patients suffering from perennial symptoms,
using uncritical short-term treatment [21] with a JAK inhibitor.
Supporting information
S1 Fig. Analysis of cells in BAL fluid by flow cytometry. The FlowJo_V10 software was used
to select BAL fluid cells on 2-D plots. First, live (7AAD negative) CD45+ leukocytes were
selected to eliminate cell debris, erythrocytes and dead cells. Then lymphocytes were gated on
SSC-Alow/CD11b- to further discriminate CD19+ B cells and CD3+ T cells. Neutrophils were
identified as SSC-Alow/GR-1+. Pre-gating on SSC-Amid-high/GR-1- cells allowed to discrimi-
nate eosinophils from macrophages by further staining of MHC-II and CD11c.
(TIF)
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S2 Fig. Analyses of murine plasma samples (Non-allergic, Allergic, Allergic-AIT, Allergic-
AIT+TOFA) after OVA-aerosol challenge. Results of the cytokine measurement for IL-4, IL-
13, IL-5, TNF-α, IFN-γ, CXCL1 and IL-10. Regarding the measurement of IL-13, a statistical
analysis was not performed, because in most of the samples IL-13 was under the detection
limit. Bars indicate the median. Gaussian and non-Gaussian distributed results were analyzed
by unpaired t test or Mann Whitney test, respectively.
(TIF)
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